https://doi.org/10.46344/JBINO.2026.v15i01.15

DIGITAL HEALTH AND WEARABLE TECHNOLOGIES IN SICKLE CELL DISEASE: ENHANCING PATIENT MONITORING AND OUTCOMES

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161, +2348037369912

ABSTRACT

Sickle cell disease remains a major global health challenge, characterized by recurrent vaso-occlusive crises, chronic pain, and multi-organ complications that require continuous clinical vigilance. Traditional models of care, often limited to episodic clinical visits, fail to capture the dynamic nature of SCD symptoms and disease progression. The emergence of digital health innovations and wearabletechnologies has revolutionized real-time monitoring, early crisis detection, and patient self-management, offering new pathways for improving outcomes. This narrative review explores the evolving role of digital health tools—including mobile health (mHealth) applications, biosensors, and telemedicine platforms—in enhancing disease monitoring, adherence, and data-driven care. Emphasis is placed on the integration of wearable devices for continuous physiologic assessment, the predictive potential of artificial intelligence in crisis forecasting, and the ethical considerations of digital care equity. Collectively, these innovations signal a transformative shift toward precision, connectivity, and patient empowerment in SCD management.

Keywords: *Sickle Cell Disease, Digital Health, Wearable Technology, Remote Monitoring, Patient Outcomes*

Introduction

Sickle cell disease (SCD) is an inherited hemoglobinopathy resulting from a single nucleotide substitution (Glu6Val) in the β-globin gene, leading to the production of sickle hemoglobin (HbS). This structural alteration causes erythrocyte deformation under hypoxic conditions, culminating in vaso-occlusion, hemolysis, and chronic systemic inflammation. Globally, over 300,000 infants are born with SCD each year, with the highest prevalence in sub-Saharan Africa, India, and the Middle East. Advances in hydroxyurea therapy, transfusion programs, and stem cell transplantation have improved survival, yet the unpredictable nature of vaso-occlusive crises (VOCs) and chronic organ damage continues to impose significant morbidity, psychosocial stress, and healthcare costs [1-2].Traditional models of care rely heavily on periodic clinic visits and self-reported symptoms, creating substantial gaps in disease monitoring. These limitations hinder timely detection of complications and delay interventions that could prevent severe crises. The increasing availability of digital health solutions and wearable technologies provides an opportunity to bridge these gaps by enabling continuous, real-time, and individualized patient monitoring. Through integration of biosensors, telemedicine platforms, and mobile applications, digital health tools are redefining how SCD patients engage with their disease and healthcare teams [3-4].This review examines how digital and wearable technologies are transforming the clinical management of SCD. It highlights their role in early crisis prediction, adherence monitoring, patient education, and long-term outcome improvement. Furthermore, it discusses challenges related to data privacy, accessibility, and equity, and explores how future integration of artificial intelligence (AI) and big data analytics can optimize care in resource-limited settings.

Digital Health in Sickle Cell Disease: A Paradigm Shift

1. Mobile Health (mHealth) Applications and Digital Platforms

Mobile health (mHealth) technologies have become integral to chronic disease management, providing platforms for data collection, patient education, and communication. In SCD, several digital tools have been developed to facilitate self-monitoring, medication adherence, and symptom tracking.Applications such as SickleCellCare, MySCTrack, and SickleSMART allow patients to log pain episodes, fatigue levels, and medication use, generating personalized data trends that can be shared with healthcare providers. These apps promote self-awareness and enable clinicians to tailor interventions based on real-world patient experiences. Studies have shown that patients using mHealth apps report improved adherence to hydroxyurea therapy, better crisis preparedness, and reduced emergency department visits.Moreover, digital platforms integrating teleconsultations and virtual follow-ups—such as TeleSCD—have demonstrated feasibility in providing remote medical guidance, particularly during travel restrictions or in rural regions. This digital shift enhances continuity of care while reducing geographic barriers to specialized services [5-8].

2. Telemedicine and Remote Consultation

Telemedicine bridges the gap between patients and healthcare providers by offering virtual consultations, digital triaging, and remote management of acute events. For individuals with SCD, who often face recurrent hospitalizations and logistical challenges in accessing care, telemedicine offers a lifeline.Through video conferencing and secure messaging, clinicians can assess early symptoms of VOCs, adjust medications, and offer psychological support without requiring in-person visits. This approach is particularly beneficial in resource-limited settings, where hematology specialists are scarce.Pilot programs in the United States and sub-Saharan Africa have demonstrated telemedicine's effectiveness in reducing unnecessary hospital visits and improving quality of life. Moreover, digital triage algorithms integrated into telehealth platforms can guide patients in distinguishing between mild and severe crises, promoting timely care-seeking behaviors and reducing preventable complications [9-11].

Wearable Technologies in Sickle Cell Disease

1. Physiologic Monitoring Devices

Wearable devices—such as smartwatches, biosensors, and wireless patches—enable continuous monitoring of physiologic parameters relevant to SCD pathophysiology. These devices track metrics such as heart rate variability, oxygen saturation (SpO_2), skin temperature, activity level, and sleep quality, offering insights into autonomic dysregulation and early signs of crisis onset.For instance, wearable pulse oximeters and photoplethysmography (PPG)-based wristbands can detect subtle oxygen desaturation events associated with impending VOCs. Similarly, heart rate and activity trackers can identify patterns of fatigue or dehydration, allowing for preemptive interventions. Combined with patient-reported data, these physiologic readings can form predictive models for crisis forecasting.Recent studies have demonstrated that deviations in SpO_2 and skin temperature may precede vaso-occlusive events by several hours, highlighting the potential for predictive analytics in crisis prevention. The integration of biosensors into mobile platforms enables remote monitoring and early alerts, empowering patients to seek care proactively before severe pain episodes occur [12-14].

2. Smart Textiles and Implantable Sensors

The development of smart fabrics and implantablebiosensors represents a frontier in continuous physiologic surveillance. Smart textiles embedded with microelectronic sensors can monitor parameters such as hydration status, hemoglobin levels, and body temperature in real time. These innovations could revolutionize pediatric and low-resource SCD care by providing noninvasive, continuous feedback without the need for repeated blood draws. Implantable sensors capable of detecting inflammatory cytokines or nitric oxide fluctuations are being investigated as next-generation diagnostic tools. Such devices could provide precise molecular-level data to guide targeted therapies and assess response to treatment [15-16].

3. Pain and Sleep Monitoring Devices

Pain is the hallmark symptom of SCD, yet its subjective nature complicates assessment and management. Wearable accelerometers and electromyography (EMG) sensors have shown promise in objectively quantifying pain-related movement patterns and sleep disturbances. Integration of these measures into digital platforms can enable real-time pain assessment, facilitating early interventions and optimizing analgesic therapy. Furthermore, continuous sleep monitoring helps identify sleep apnea and nocturnal hypoxia—conditions that exacerbate VOC frequency—thereby guiding lifestyle and therapeutic adjustments [17].

Integrating Artificial Intelligence and Predictive Analytics

The fusion of AI and predictive analytics with digital health represents a transformative leap in the management of SCD. These technologies promise to shift care paradigms from reactive crisis management to proactive prediction and prevention—an evolution that aligns with the complex, fluctuating nature of SCD. By analyzing vast amounts of data generated from wearable devices, mobile health applications, and electronic health records (EHRs), AI systems can detect subtle physiological and environmental signals that precede vaso-occlusive crises (VOCs) and other complications.In SCD, the pathophysiological events leading to a crisis often begin hours before clinical symptoms appear, involving processes such as hemoglobin polymerization, endothelial activation, and microvascular occlusion. Continuous monitoring through digital devices captures real-time parameters—such as heart rate variability, oxygen saturation, skin temperature, and activity patterns—that fluctuate with disease dynamics. When these data streams are analyzed using AI algorithms, they can reveal hidden patterns and correlations beyond human perception. Machine learning (ML) models can thus generate predictivealerts that warn patients and clinicians of an impending crisis, allowing early interventions such as hydration, rest, or analgesic administration [18-20].

Emerging studies have demonstrated the feasibility of such approaches. For instance, ML-based models trained on wearable biosensor data have successfully identified pre-crisis physiological signatures, including reductions in oxygen saturation and increases in heart rate variability. Similarly, AI-driven digital platforms integrating meteorological data—such as temperature, humidity, and air pollution—can predict environmental triggers of VOCs, empowering patients to modify their activities accordingly. These predictive systems represent the foundation of personalizeddigitalcare, where interventions are tailored to each patient's physiologic profile and environmental exposure [21-22].Beyond crisis prediction, AI and predictive analytics extend to broader dimensions of SCD management. Natural language processing (NLP) tools can analyze patient-reported symptoms and clinician notes to identify patterns of pain, fatigue, or emotional distress over time. Predictive algorithms applied to EHRs can forecast long-term complications such as stroke, pulmonary hypertension, or nephropathy, enabling targeted surveillance and preventive care. Deep learning methods are also being applied to medical imaging and laboratory data to refine diagnostic precision, detect early organ damage, and evaluate response to therapy [23].

A particularly promising avenue lies in the development of "digitaltwins"—virtual replicas of individual patients created using AI and big data integration. These digital avatars simulate physiological processes, allowing clinicians to model disease progression and test virtual interventions before applying them in real life. In SCD, a digital twin could predict how a specific patient might respond to changes in therapy, environmental stress, or hydration status, providing a safe and individualized decision-making tool [24].The integration of AI into digital health ecosystems also facilitates adaptivelearning, where algorithms continuously refine their predictive accuracy as they receive new data. Over time, such systems evolve to better understand the nuances of each patient's condition, offering increasingly precise recommendations. When connected to wearable devices and cloud-based monitoring systems, AI-driven tools can serve as digital companions—alerting patients to risk states, guiding lifestyle choices, and assisting clinicians in optimizing care plans [25].However, the potential of AI in SCD care extends beyond individual monitoring. At the population level, aggregated anonymized data can help identify epidemiological patterns, regional disparities, and predictors of healthcare utilization. Health policymakers and researchers can use these insights to design data-driven interventions, allocate resources effectively, and evaluate public health programs [26].

Impact on Patient Outcomes and Quality of Life

The incorporation of digital health technologies and wearable devices into SCD management has profound implications for both clinical outcomes and patientqualityoflife. By enabling real-time monitoring, early detection of complications, and continuous engagement with healthcare teams, these innovations are reshaping how patients experience, manage, and live with the disease.

1. Early Detection and Prevention of Crises

VOCs are the hallmark of SCD, often unpredictable and debilitating, leading to acute pain, hospitalization, and long-term organ damage. Wearable devices that continuously monitor physiological parameters—such as oxygen saturation, heart rate variability, and skin temperature—allow for early identification of subtle deviations that precede crises. When combined with AI-driven predictive algorithms, these systems can generate alertsforimpendingVOCs, prompting patients to initiate preventive measures such as hydration, rest, or timely analgesic use. By reducing the frequency, severity, and duration of crises, digital health interventions directly mitigate morbidity and healthcare utilization [27].

2. Improved Adherence and Medication Management

Medication adherence is a critical determinant of SCD outcomes, particularly for disease-modifying therapies such as hydroxyurea. Mobile health applications and wearable-linked platforms facilitate reminders, adherence tracking, and motivational support, encouraging patients to maintain consistent therapy. Real-time adherence data also allow clinicians to intervene proactively, adjusting dosing schedules or providing counseling to address barriers. Improved adherence translates to higher fetal hemoglobin levels, fewer crises, and decreased risk of complications, reinforcing both clinical and quality-of-life benefits [28].

3. Enhanced Patient Empowerment and Self-Management

Digital health tools empower patients by fostering active engagement with their disease. Logging symptoms, monitoring physiologic trends, and receiving personalized feedback cultivates self-awareness and confidence in managing day-to-day health. Patients gain greater control over lifestyle modifications, such as activity pacing, hydration, and avoidance of environmental triggers, which can reduce VOC incidence. This sense of agency diminishes psychological distress, promotes self-efficacy, and enhances overall well-being, contributing to a more positive patient experience [29].

4. Reduced Healthcare Utilization and Financial Burden

Frequent emergency visits and hospitalizations are major contributors to the economic and social burden of SCD. Digital health platforms, telemedicine consultations, and remote monitoring reduce unnecessary clinic visits and allow timely outpatient management of early crises. Studies have shown that patients using wearable sensors and mHealth applications experience fewer hospital admissions and shorter lengths of stay, which not only reduce healthcare costs but also minimize disruptions to education, employment, and family life. This reduction in healthcare utilization is particularly meaningful in resource-limited settings, where access to specialized care is often constrained [30].

5. Improved Psychosocial Outcomes and Quality of Life

SCD significantly impacts psychosocial well-being due to chronic pain, fatigue, and activity limitations. Wearable technologies and digital monitoring contribute to improved emotionalhealth by providing reassurance, supporting self-monitoring, and facilitating timely clinical intervention. Telemedicine platforms offer continuous access to healthcare professionals and peer-support networks, which alleviates feelings of isolation and enhances coping strategies. By integrating physical, emotional, and behavioral data, these tools enable a holisticapproach to care that addresses both medical and psychosocial dimensions of SCD [31].

6. Personalized and Predictive Care for Long-Term Outcomes

Continuous data collection and predictive analytics enable individualized care plans that anticipate complications such as pulmonary hypertension, nephropathy, or stroke. By tailoring interventions to each patient's unique physiological and environmental profile, digital health solutions can optimize long-term outcomes, reduce cumulative organ damage, and extend life expectancy. This personalized approach not only improves survival but also enhances the overall quality of life, allowing patients to engage more fully in education, employment, and social activities [32].

7. Fostering Patient-Clinician Collaboration

The integration of digital data into clinical workflows strengthens the therapeutic alliance. Shared access to physiologic trends, symptom logs, and predictive alerts allows clinicians to make informed, timely decisions and facilitates shared decision-making. Patients experience greater trust, satisfaction, and adherence to care recommendations, further reinforcing positive outcomes [33].

Challenges and Ethical Considerations

While digital health and wearable technologies hold tremendous promise for transforming the management of SCD, their implementation is accompanied by multifaceted challenges spanning technological, ethical, social, and policy domains. Addressing these issues is essential to ensure that innovation translates into equitable and sustainable clinical impact, particularly in the resource-limited regions where SCD is most prevalent.

1. Data Privacy, Security, and Ownership

One of the foremost ethical challenges in digital health lies in the protection of sensitive patient data. Wearables, mobile applications, and telemedicine platforms collect vast amounts of personal health information, including physiologic parameters, geolocation data, and behavioral patterns. Without robust cybersecurity measures, these datasets are vulnerable to unauthorized access, breaches, or misuse.In many low- and middle-income countries (LMICs), health data governance frameworks remain underdeveloped, raising concerns about who owns and controls patient-generated data. The lack of uniform regulatory standards such as the General Data Protection Regulation (GDPR) **or** Health Insurance Portability and Accountability Act (HIPAA) equivalents limits accountability. Patients must be assured of informed consent, data encryption, and transparent data-sharing policies before engaging with digital platforms. Establishing secure, interoperable systems that protect confidentiality while facilitating clinical access remains a critical priority [34].

2. Digital Divide and Health Equity

Despite their potential to enhance care, digital health innovations risk widening existing health disparities if equitable access is not ensured. Many individuals with SCD reside in low-resource settings where internet connectivity, smartphone ownership, and electricity access are limited. Furthermore, the cost of wearable devices and subscription-based digital services may be prohibitive for economically disadvantaged populations.This digitaldivide extends beyond access to infrastructure—it encompasses disparities in digital literacy, language barriers, and user familiarity with technology. Without deliberate inclusion strategies, digital health may inadvertently benefit only a privileged subset of patients. Addressing these inequities requires public-private partnerships to subsidize technology costs, community education initiatives to enhance digital competence, and culturally adaptive user interfaces to ensure inclusivity [35].

3. Algorithmic Bias and Reliability of Artificial Intelligence Systems

AI and ML models underpinning predictive analytics in digital SCD care rely heavily on large datasets for training and validation. However, if these datasets are not representative of diverse patient populations, algorithmicbias can emerge—leading to inaccurate predictions or unequal clinical outcomes. For instance, models trained primarily on data from high-income countries may not accurately capture the environmental and genetic nuances affecting patients in sub-Saharan Africa or India.Ensuring algorithmictransparency, continuous model validation, and inclusion of diverse datasets is vital to preventing digital marginalization. Furthermore, AI-driven alerts or predictions must always be interpreted in conjunction with clinical judgment to avoid over-reliance on automated systems. Human oversight remains central to ethical and effective digital health deployment [36].

4. Regulatory and Legal Frameworks

The integration of wearable and digital health devices into clinical care introduces regulatory complexities regarding device approval, data usage, and medical accountability. Many wearable devices used by patients are consumer-grade products that lack clinical validation or regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA) **or** European Medicines Agency (EMA)**.** This creates uncertainty about data reliability, interoperability with clinical systems, and liability in case of harm due to device malfunction or false readings.Developing clear regulatorypathways for the approval and certification of digital health tools is necessary to ensure safety and efficacy. Moreover, establishing international standards for interoperability can facilitate the seamless exchange of data between wearable devices, mobile applications, and electronic health records[37].

5. Patient Autonomy, Consent, and Psychological Implications

Digital health technologies inherently alter the patient-clinician dynamic. While they empower patients with greater autonomy, they also raise questions about informed consent and the psychological burden of constant self-monitoring. Continuous data collection can lead to data fatigue or healthanxiety, where patients become overly vigilant or stressed about minor fluctuations in their readings.Ethical digital health implementation must balance empowerment with emotional well-being. Patients should receive adequate training on interpreting data and be supported through digital counseling or virtual care coaching. Consent processes should be iterative—allowing patients to periodically review and adjust their participation preferences [38].

6. Implementation Barriers and Sustainability

Integrating digital and wearable technologies into existing healthcare systems requires substantial investment in infrastructure, staff training, and maintenance. In many healthcare settings, especially in sub-Saharan Africa, challenges such as limited internet bandwidth, unstable power supply, and lack of skilled personnel hinder scalability. Furthermore, pilot projects often fail to transition into sustained clinical programs due to short-term funding cycles and lack of local ownership.To ensure sustainability, digital health initiatives must be embedded within national health strategies and supported by long-term funding models. Local capacity building, public-private collaborations, and engagement with patient advocacy groups are vital for ensuring both technological sustainability and community trust [39].

7. Ethical Imperative for Global Inclusion

Finally, as digital medicine advances, there is an ethical obligation to ensure globalinclusivity. Sickle cell disease disproportionately affects populations in Africa, the Caribbean, and parts of Asia—regions that are often underrepresented in digital health research and innovation. Without proactive efforts to include these populations in technology design, testing, and implementation, digital health could perpetuate global health inequities.Ethical frameworks should prioritize co-creation with affected communities, ensuring that technologies are culturally sensitive, linguistically appropriate, and locally relevant. Moreover, global health organizations must advocate for equitable funding and technology transfer to enable low-resource regions to benefit from digital transformation (Table 1) [40].

Table 1: Summary of Key Ethical and Implementation Challenges in Digital SCD Care

Challenge	Description	Proposed Ethical/Strategic Response
Data privacy and security	Risk of unauthorized access to personal health data collected by wearables and apps	Implement encryption, informed consent, and standardized data protection frameworks (e.g., HIPAA/GDPR compliance)
Digital divide	Limited access to internet, smartphones, and wearables in resource-limited regions	Subsidize devices, expand broadband access, and enhance digital literacy programs
Algorithmic bias	Inaccurate AI predictions due to non-representative datasets	Train algorithms on diverse populations; ensure human oversight and transparency
Regulatory uncertainty	Lack of clear approval and oversight pathways for digital devices	Develop international regulatory standards and certification for clinical use
Psychological burden	Data fatigue or anxiety from continuous self-monitoring	Provide digital counseling, patient education, and consent flexibility
Implementation sustainability	Infrastructure and funding limitations in LMICs	Embed digital health into national health strategies with long-term support
Global equity	Underrepresentation of high-prevalence populations in research	Promote inclusion, local innovation, and equitable access to technology

Conclusion

Digital health and wearable technologies are revolutionizing the management of sickle cell disease by bridging the gap between clinical observation and real-time patient experience. Through continuous monitoring, remote consultation, and data-driven intervention, these innovations empower patients, enhance disease control, and improve outcomes. While challenges of accessibility, affordability, and ethics remain, the integration of AI-driven analytics and precision monitoring offers a pathway to a more equitable and connected future for SCD care. The convergence of technology and hematology thus holds the promise of redefining how chronic hemoglobinopathies are understood, treated, and lived.

References

1. Inusa, B. P. D., Hsu, L. L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K. A., &Atoyebi, W. (2019). Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. *International journal of neonatal screening*, *5*(2), 20. https://doi.org/10.3390/ijns5020020
2. Salinas Cisneros, G., & Thein, S. L. (2020). Recent Advances in the Treatment of Sickle Cell Disease. *Frontiers in physiology*, *11*, 435. https://doi.org/10.3389/fphys.2020.00435
3. Adewoyin A. S. (2015). Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa). *Anemia*, *2015*, 791498. https://doi.org/10.1155/2015/791498
4. Liu, J., Yang, L., Liu, D., Wu, Q., Yu, Y., Huang, X., Li, J., & Liu, S. (2025). The role of multi-omics in biomarker discovery, diagnosis, prognosis, and therapeutic monitoring of tissue repair and regeneration processes. *Journal of orthopaedic translation*, *54*, 131–151. https://doi.org/10.1016/j.jot.2025.07.006
5. Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. *Frontiers in oncology*, *10*, 1387. https://doi.org/10.3389/fonc.2020.01387
6. Kalpatthi, R., &Novelli, E. M. (2018). Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. *Hematology. American Society of Hematology. Education Program*, *2018*(1), 482–492. https://doi.org/10.1182/asheducation-2018.1.482
7. Conran, N., & Belcher, J. D. (2018). Inflammation in sickle cell disease. *Clinical hemorheology and microcirculation*, *68*(2-3), 263–299. https://doi.org/10.3233/CH-189012
8. Ansari, J., &Gavins, F. N. E. (2019). Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. *The American journal of pathology*, *189*(4), 706–718. https://doi.org/10.1016/j.ajpath.2018.12.012
9. Dash, U. C., Bhol, N. K., Swain, S. K., Samal, R. R., Nayak, P. K., Raina, V., Panda, S. K., Kerry, R. G., Duttaroy, A. K., & Jena, A. B. (2025). Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. *Acta pharmaceuticaSinica. B*, *15*(1), 15–34. https://doi.org/10.1016/j.apsb.2024.10.004
10. S, S., Hegde, S. V., Agarwal, S. V., Ns, D., Pillai, A., Shah, S. N., & S, R. (2024). Biomarkers of Oxidative Stress and Their Clinical Relevance in Type 2 Diabetes Mellitus Patients: A Systematic Review. *Cureus*, *16*(8), e66570. https://doi.org/10.7759/cureus.66570
11. Mohammad, S. N. N. A., Iberahim, S., Wan Ab Rahman, W. S., Hassan, M. N., Edinur, H. A., Azlan, M., &Zulkafli, Z. (2022). Single Nucleotide Polymorphisms in *XMN1-HBG2*, *HBS1L-MYB*, and *BCL11A* and Their Relation to High Fetal Hemoglobin Levels That Alleviate Anemia. *Diagnostics (Basel, Switzerland)*, *12*(6), 1374. https://doi.org/10.3390/diagnostics12061374

12. Mikobi, T. M., TshiloboLukusa, P., Aloni, M. N., Lumaka, A. Z., Kaba, D. K., Devriendt, K., Matthijs, G., MbuyiMuamba, J. M., & Race, V. (2018). Protective BCL11A and HBS1L-MYB polymorphisms in a cohort of 102 Congolese patients suffering from sickle cell anemia. *Journal of clinical laboratory analysis*, *32*(1), e22207. https://doi.org/10.1002/jcla.22207
13. Smith, A., & McCulloh, R. J. (2015). Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. *Frontiers in physiology*, 6, 187. https://doi.org/10.3389/fphys.2015.00187
14. Schaer, D. J., Vinchi, F., Ingoglia, G., Tolosano, E., & Buehler, P. W. (2014). Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. *Frontiers in physiology*, *5*, 415. https://doi.org/10.3389/fphys.2014.00415
15. Heeney, M. M., & Ware, R. E. (2010). Hydroxyurea for children with sickle cell disease. *Hematology/oncology clinics of North America*, *24*(1), 199–214. https://doi.org/10.1016/j.hoc.2009.11.002
16. Bodaghi, A., Fattahi, N., & Ramazani, A. (2023). Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. *Heliyon*, *9*(2), e13323. https://doi.org/10.1016/j.heliyon.2023.e13323
17. Qoronfleh, M. W., & Al-Dewik, N. (2025). Cancer Biomarkers: Reflection on Recent Progress, Emerging Innovations, and the Clinical Horizon. *Cancers*, *17*(18), 2981. https://doi.org/10.3390/cancers17182981
18. Abraham, A. A., & Tisdale, J. F. (2021). Gene therapy for sickle cell disease: moving from the bench to the bedside. *Blood*, *138*(11), 932–941. https://doi.org/10.1182/blood.2019003776
19. Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022). Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease. *Cells*, *11*(11), 1843. https://doi.org/10.3390/cells11111843
20. Gaj, T., Gersbach, C. A., &Barbas, C. F., 3rd (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. *Trends in biotechnology*, *31*(7), 397–405. https://doi.org/10.1016/j.tibtech.2013.04.004
21. Obeagu, E. I., &Obeagu, G. U. (2024). Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. *Medicine*, *103*(20), e38164. https://doi.org/10.1097/MD.0000000000038164
22. Obeagu E. I. (2024). Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. *Annals of medicine and surgery (2012)*, *86*(3), 1570–1574. https://doi.org/10.1097/MS9.0000000000001763
23. Gaj, T., Sirk, S. J., Shui, S. L., & Liu, J. (2016). Genome-Editing Technologies: Principles and Applications. *Cold Spring Harbor perspectives in biology*, *8*(12), a023754. https://doi.org/10.1101/cshperspect.a023754
24. Watts, J. K., & Corey, D. R. (2012). Silencing disease genes in the laboratory and the clinic. *The Journal of pathology*, *226*(2), 365–379. https://doi.org/10.1002/path.2993
25. Zhu, Y., Zhu, L., Wang, X., &Jin, H. (2022). RNA-based therapeutics: an overview and prospectus. *Cell death & disease*, *13*(7), 644. https://doi.org/10.1038/s41419-022-05075-2

26. Glaros, A. K., Razvi, R., Shah, N., & Zaidi, A. U. (2021). Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. *Therapeutic advances in hematology*, *12*, 20406207211001136. https://doi.org/10.1177/20406207211001136
27. Bhalla, N., Bhargav, A., Yadav, S. K., & Singh, A. K. (2023). Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review. *Frontiers in medicine*, *10*, 1036939. https://doi.org/10.3389/fmed.2023.1036939
28. Obeagu, E. I., &Obeagu, G. U. (2024). Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. *Medicine*, *103*(17), e37941. https://doi.org/10.1097/MD.0000000000037941
29. Obeagu, E. I., &Obeagu, G. U. (2024). Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. *Medicine*, *103*(18), e38075. https://doi.org/10.1097/MD.0000000000038075
30. Gyurkocza, B., Rezvani, A., &Storb, R. F. (2010). Allogeneic hematopoietic cell transplantation: the state of the art. *Expert review of hematology*, *3*(3), 285–299. https://doi.org/10.1586/ehm.10.21
31. Khurana, K., Mahajan, S., Acharya, S., Kumar, S., &Toshniwal, S. (2024). Clinical Biomarkers of Acute Vaso-Occlusive Sickle Cell Crisis. *Cureus*, *16*(3), e56389. https://doi.org/10.7759/cureus.56389
32. Silva, D. G., Belini Junior, E., Carrocini, G. C., Torres, L.deS., Ricci Júnior, O., Lobo, C. L., Bonini-Domingos, C. R., & de Almeida, E. A. (2013). Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia. *BMC medical genetics*, *14*, 108. https://doi.org/10.1186/1471-2350-14-108
33. McGann, P. T., & Ware, R. E. (2015). Hydroxyurea therapy for sickle cell anemia. *Expert opinion on drug safety*, *14*(11), 1749–1758. https://doi.org/10.1517/14740338.2015.1088827
34. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. *Molecular cancer*, *23*(1), 9. https://doi.org/10.1186/s12943-023-01925-5
35. Lee, T. L., & Sawai, T. (2024). Navigating equity in global access to genome therapy expanding access to potentially transformative therapies and benefiting those in need requires global policy changes. *Frontiers in genetics*, *15*, 1381172. https://doi.org/10.3389/fgene.2024.1381172
36. Djordjevic, D., McFadyen, A., & Anderson, J. A. (2023). Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. *The journal of medicine access*, *7*, 27550834231177507. https://doi.org/10.1177/27550834231177507
37. Wang, S. X., Huang, Z. F., Li, J., Wu, Y., Du, J., & Li, T. (2024). Optimization of diagnosis and treatment of hematological diseases via artificial intelligence. *Frontiers in medicine*, *11*, 1487234. https://doi.org/10.3389/fmed.2024.1487234
38. Obeagu, E. I., &Obeagu, G. U. (2024). Implications of climatic change on sickle cell anemia: A review. *Medicine*, *103*(6),

e37127. https://doi.org/10.1097/MD.0000000000037127

39. Obeagu, E. I., Ubosi, N. I., Obeagu, G. U., Egba, S. I., & Bluth, M. H. (2024). Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. *Medicine*, *103*(2), e36898. https://doi.org/10.1097/MD.0000000000036898

40. Obeagu, E. I., &Obeagu, G. U. (2024). Telomere Dynamics in Sickle Cell Anemia: Unraveling Molecular Aging and Disease Progression. *Journal of blood medicine*, *15*, 313–323. https://doi.org/10.2147/JBM.S462758